Phaseline

Targets › TLR4

TLR4 (Toll-like receptor 4): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Other, Gastroenterology, Psychiatry; next expected readout Dec 2026.

Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways. At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). (UniProt, O00206)

Open in Phaseline: the race on TLR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
YaqritResatorvid (TAK-242)
Toll-like receptor 4 inhibitor
TLR4Phase 2Acute-On-Chronic Liver FailureAug 2028
Singapore General HospitalAS01 adjuvant
Toll-like receptor agonist; immunological adjuvant containing MPL and QS21
TLR4Phase 2Immune System Responses and Trained Immunity After AS01 AdministrationFeb 2029
Laureate Institute for Brain Research, Inc.Lipopolysaccharide (LPS)
Toll-like receptor 4 (TLR4) agonist; endotoxin that activates innate immune response
TLR4Phase 1Major Depressive DisorderDec 2026

Conditions

Immune System Responses and Trained Immunity After AS01 Administration (1) Acute-On-Chronic Liver Failure (1) Major Depressive Disorder (1)

Modalities

protein or peptide (2), mixed (1)

Companies

Singapore General Hospital (1) Yaqrit (1) Laureate Institute for Brain Research, Inc. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.